Search

Your search keyword '"Gritti G"' showing total 18 results
Start Over Author "Gritti G" Publisher wiley
18 results on '"Gritti G"'

1. COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Author

Hutchings, M., primary, Dickinson, M., additional, Carlo‐Stella, C., additional, Morschhauser, F., additional, Bosch, F., additional, Gritti, G., additional, Townsend, W., additional, Bartlett, N. L., additional, Cartron, G., additional, Ghesquieres, H., additional, Houot, R., additional, Walter, H., additional, Offner, F., additional, Christiansen, A., additional, Dimier, N., additional, Jamois, C., additional, Harrop, E., additional, Herter, S., additional, Hölzlwimmer, G., additional, Keelara, A., additional, Korfi, K., additional, Luong, J., additional, Mueller, C., additional, Mycroft, S., additional, Whayman, M., additional, Prieto, I., additional, Rukina, D., additional, and Lechner, K., additional

Published
2023
Full Text
View/download PDF

2. GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Hutchings, M., primary, Avigdor, A., additional, Sureda, A., additional, Terol, M. J., additional, Bosch, F., additional, Corradini, P., additional, Larsen, T. Stauffer, additional, Domínguez, A. Rueda, additional, Skarbnik, A., additional, Jørgensen, J., additional, Goldschmidt, N., additional, Gurion, R., additional, Zinzani, P. L., additional, Pinto, A., additional, Cordoba, R., additional, Bottos, A., additional, Huang, Z., additional, Simko, S., additional, Relf, J., additional, Filézac de L’Etang, A., additional, Sellam, G., additional, and Gritti, G., additional

Published
2023
Full Text
View/download PDF

3. P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY

Author

Bachy, E., primary, Savage, K. J., additional, Huang, H., additional, Kwong, Y. L., additional, Gritti, G., additional, Zhang, Q., additional, Liberati, A. M., additional, Cao, J., additional, Yang, H., additional, Hao, S., additional, Hu, J., additional, Zhou, K., additional, Russo, F., additional, Zhang, H., additional, Sang, W., additional, Ji, J., additional, Ferreri, A. J. M., additional, Damaj, G. L., additional, Liu, H., additional, Zhang, W., additional, Ke, X., additional, Ghiggi, C., additional, Huang, S., additional, Li, X., additional, Yao, H., additional, Paik, J., additional, Novotny, W., additional, Zhou, W., additional, Zhu, H., additional, Huang, J., additional, and Zinzani, P. L., additional

Published
2022
Full Text
View/download PDF

4. P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

Author

Zinzani, P. L., primary, Zain, J., additional, Mead, M., additional, Casulo, C., additional, Jacobsen, E. D., additional, Gritti, G., additional, Pinter-Brown, L., additional, Isutzu, K., additional, Cohan, D., additional, Daugherty, M., additional, Brammer, J. E., additional, Mehta-Shah, N., additional, Pro, B., additional, and Horwitz, S. M., additional

Published
2022
Full Text
View/download PDF

5. POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

Author

Bannerji, R., primary, Yuen, S., additional, Phillips, T., additional, Arthur, C., additional, Isufi, I., additional, Marlton, P., additional, Seymour, J. F., additional, Corradini, P., additional, Molinari, A., additional, Gritti, G., additional, Emmons, R., additional, Hirata, J., additional, Musick, L., additional, Saha, S., additional, Croft, B., additional, and Flowers, C., additional

Published
2021
Full Text
View/download PDF

6. NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY

Author

Zinzani, P. L., primary, Santoro, A., additional, Gritti, G., additional, Brice, P., additional, Barr, P. M., additional, Kuruvilla, J., additional, Cunningham, D., additional, Kline, J., additional, Johnson, N. A., additional, Mehta‐Shah, N., additional, Fanale, M., additional, Francis, S., additional, and Moskowitz, A. J., additional

Published
2021
Full Text
View/download PDF

8. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA

Author

Ceriani, L, primary, Milan, L, additional, Cascione, L, additional, Gritti, G, additional, Dalmasso, F, additional, Esposito, F, additional, Schär, Säm, additional, Bruno, A, additional, Dirnhofer, S, additional, Giovanella, L, additional, Hayoz, S, additional, Mamot, C, additional, Rambaldi, A, additional, Chauvie, S, additional, and Zucca, E, additional

Published
2021
Full Text
View/download PDF

9. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

Bonfiglio, F., primary, Bruscaggin, A., additional, Guidetti, F., additional, Terzi di Bergamo, L., additional, Faderl, M., additional, Spina, V., additional, Condoluci, A., additional, Bonomini, L., additional, Forestieri, G., additional, Koch, R., additional, Piffaretti, D., additional, Pini, K., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Arribas, A., additional, Lucioni, M., additional, Ghilardi, G., additional, Wu, W., additional, Arcaini, L., additional, Baptista, M. J., additional, Bastidas, G., additional, Bea, S., additional, Boldorini, R., additional, Broccoli, A., additional, Canzonieri, V., additional, Cascione, L., additional, Ceriani, L., additional, Cogliatti, S., additional, Derenzini, E., additional, Devizzi, L., additional, Dietrich, S., additional, Elia, A. R., additional, Facchetti, F., additional, Gaidano, G., additional, Garcia, J. F., additional, Gerber, B., additional, Ghia, P., additional, Silva, M. G., additional, Gritti, G., additional, Guidetti, A., additional, Hitz, F., additional, Inghirami, G., additional, Ladetto, M., additional, Lopez‐Guillermo, A., additional, Lucchini, E., additional, Maiorana, A., additional, Marasca, R., additional, Matutes, E., additional, Meignin, V., additional, Merli, M., additional, Moccia, A., additional, Mollejo, M., additional, Montalban, C., additional, Novak, U., additional, Oscier, D. G., additional, Passamonti, F., additional, Piazza, F., additional, Pizzolitto, S., additional, Sabattini, E., additional, Salles, G., additional, Santambrogio, E., additional, Scarfó, L., additional, Stathis, A., additional, Stüssi, G., additional, Geyer, J. T., additional, Tapia, G., additional, Thieblemont, C., additional, Tousseyn, T., additional, Tucci, A., additional, Visco, C., additional, Vitolo, U., additional, Zenz, T., additional, Zinzani, P. L., additional, Khiabanian, H., additional, Calcinotto, A., additional, Bertoni, F., additional, Bhagat, G., additional, Campo, E., additional, Leval, L., additional, Dirnhofer, S., additional, Pileri, S. A., additional, Piris, M. Án., additional, Traverse‐Glehen, A., additional, Tzankov, A., additional, Paulli, M., additional, Ponzoni, M., additional, Mazzucchelli, L., additional, Cavalli, F., additional, Zucca, E., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

10. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT

Author

Ceriani, L., primary, Pirosa, M., additional, Stathis, A., additional, Gritti, G., additional, Ruberto, T., additional, Bruno, A., additional, Moccia, A., additional, Rambaldi, A., additional, Ferrari, S., additional, Giovannella, L., additional, Hayoz, S., additional, Mazzucchelli, L., additional, Dirnhofer, S., additional, Mamot, C., additional, and Zucca, E., additional

Published
2019
Full Text
View/download PDF

12. R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL

Author

Ferreri, A. J., primary, Calimeri, T., additional, Conte, G., additional, Ponzoni, M., additional, Fallanca, F., additional, Cattaneo, D., additional, Scarano, E., additional, Flavio, C., additional, Sassone, M., additional, Foppoli, M., additional, Perrone, S., additional, Cecchetti, C., additional, Lopedote, P., additional, Gritti, G., additional, Castellino, C., additional, Verga, L., additional, Olcese, F., additional, Mazza, R., additional, Ciceri, F., additional, Bordignon, C., additional, Anzalone, N., additional, and Corti, A., additional

Published
2019
Full Text
View/download PDF

13. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B- AND T-CELL LYMPHOMAS

Author

Tarantelli, C., primary, Lange, M., additional, Gaudio, E., additional, Cascione, L., additional, Spriano, F., additional, Kwee, I., additional, Arribas, A., additional, Rinaldi, A., additional, Jourdan, T., additional, Berthold, M., additional, Margheriti, F., additional, Gritti, G., additional, Rossi, D., additional, Stathis, A., additional, Liu, N., additional, Zucca, E., additional, Politz, O., additional, and Bertoni, F., additional

Published
2019
Full Text
View/download PDF

14. NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY

Author

Zinzani, P.L., primary, Santoro, A., additional, Gritti, G., additional, Brice, P., additional, Barr, P.M., additional, Kuruvilla, J., additional, Cunningham, D., additional, Kline, J., additional, Johnson, N.A., additional, Mehta-Shah, N.A., additional, Manley, T., additional, Francis, S., additional, Sharma, M., additional, and Moskowitz, A.J., additional

Published
2019
Full Text
View/download PDF

15. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY

Author

Kaplan, J., primary, Gordon, L., additional, Infante, J., additional, Popat, R., additional, Rambaldi, A., additional, Madan, S., additional, Patel, M.R., additional, Gritti, G., additional, El-Sharkawi, D., additional, Chau, I., additional, Radford, J., additional, Perez De Oteyza, J., additional, Zinzani, P., additional, Iyer, S., additional, Faucette, S., additional, Sheldon-Waniga, E., additional, Stumpo, K., additional, Shou, Y., additional, Carpio, C., additional, and Bosch, F., additional

Published
2017
Full Text
View/download PDF

18. Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.

Author

Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, and Matera MG

Subjects
Adrenergic beta-1 Receptor Antagonists administration & dosage, Adrenergic beta-2 Receptor Agonists administration & dosage, Animals, Blood Pressure drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Therapy, Combination, Heart Failure physiopathology, Heart Rate drug effects, Indans administration & dosage, Male, Metoprolol administration & dosage, Myocardial Infarction physiopathology, Quinolones administration & dosage, Rats, Rats, Wistar, Adrenergic beta-1 Receptor Antagonists pharmacology, Adrenergic beta-2 Receptor Agonists pharmacology, Heart Failure drug therapy, Indans pharmacology, Metoprolol pharmacology, Myocardial Infarction drug therapy, Quinolones pharmacology, Receptors, Adrenergic, beta metabolism, Ventricular Remodeling drug effects
Abstract

Background and Purpose: The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2 -adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF)., Experimental Approach: We investigated the effects of indacaterol and metoprolol, administered alone or in combination, on myocardial histology, β-adrenoceptor-mediated pathways, markers of remodelling and haemodynamic parameters in a rat model of HF. Five groups of rats were assessed: sham-operated rats; HF rats; HF + indacaterol 0.3 mg·kg(-1) ·day(-1) ; HF + metoprolol 100 mg·kg(-1) ·day(-1) ; HF + metoprolol + indacaterol. All pharmacological treatments continued for 15 weeks., Key Results: Treatment with either indacaterol or metoprolol significantly reduced the infarct size in HF rats. However, the combination of indacaterol and metoprolol reduced the infarct size even further, reduced both BP and heart rate, reversed the decrease in ejection fraction, normalized left ventricular systolic and diastolic internal diameters, normalized the decreased β1 adrenoceptor mRNA expression as well as cardiac cAMP levels and reduced cardiac GPCR kinase 2 expression, compared with the untreated HF group., Conclusion and Implications: The results of our study demonstrated an additive interaction between indacaterol and metoprolol in normalizing and reversing cardiac remodelling in our experimental model of HF. The translation of these findings to clinical practice might be of interest, as this combination of drugs could be safer and more effective in patients suffering from HF and COPD., (© 2015 The British Pharmacological Society.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results